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Abstract
Gender medicine focuses on the patho-physiological, 
clinical, prevention and treatment differences in dis-
eases that are equally represented in men and women. 
The purpose of gender medicine is to ensure that each 
individual man and woman receives the best treatment 
possible based on scientific evidence. The concept of 
“gender” includes not only the sexual characteristics 
of individuals but also physiological and psychological 
attributes of men and women, including risk factors, 
protective/aggravating effects of sexual hormones 
and variances linked to genetics and corporal struc-
tures that explain biological and physiological differ-
ences between men and women. It is very important 
to consider all the biological, physiological, functional, 
psychological, social and cultural characteristics to pro-
vide patients with individualized disease management. 
Herein, we critically analyze the literature regarding 
gender differences for diseases and acquired conditions 
of the most representative hepatic pathologies: primary 
biliary cirrhosis, autoimmune hepatitis, primary scleros-
ing cholangitis, non alcoholic fatty liver disease and 
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alcoholic liver disease, and viral chronic hepatitis B and 
C. The last section addresses hemochromatosis, which 
is a prevalent iron overload disorder in the Caucasian 
population. This review aims to describe data from the 
literature concerning viral chronic hepatitis during preg-
nancy, management during pregnancy and delivery, 
and new effective drugs for the prevention of maternal 
infection transmission without significant adverse ef-
fects or complications.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Gender medicine focuses on the patho-physi-
ological, clinical, prevention and treatment differences 
in diseases that are equally represented in men and 
women. The concept of “gender” includes not only the 
sexual characteristics of individuals but also physiologi-
cal and psychological attributes of men and women. In 
this review, we critically analyze the literature regarding 
gender differences for diseases and acquired condi-
tions of the most representative hepatic pathologies: 
primary biliary cirrhosis, autoimmune hepatitis, primary 
sclerosing cholangitis, non alcoholic fatty liver disease 
and alcoholic liver disease, viral chronic hepatitis B and 
C, and hemochromatosis (the prevalent iron overload 
disorder in the Caucasian population).
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INTRODUCTION
Gender medicine is a new aspect of  medicine that fo-
cuses on to investigating the differences in diseases based 
on anatomic and physiological stages, from biological, 
functional, psychological, social and cultural points of  
view and analyzes the range of  responses to pharmaco-
logical care. This field emerged because epidemiological 
and clinical surveys performed over the last 30 years have 
generally reported results for only gender[1].
The concept of  “gender” refers not only to the sexual 
characteristics of  individuals, but also to a set of  differ-
ences derived from the physiology and psychology of  
men and women and from various social and cultural 
environments. From biological and physiological points 
of  view, the differences between men and women may be 
explained by differences in the presence of  risk factors, 
protective/aggravating effects of  sexual hormones, vari-
ances linked to genetics and various corporal structures[2].
The aim of  this review is to examine the available 
data in the literature concerning the differences between 
men and women for the most representative hepatic pa-
thologies, including primary biliary cirrhosis (PBC), auto-
immune hepatitis (AIH), viral chronic hepatitis B and C, 
non alcoholic fatty liver disease (NAFLD) and alcoholic 
liver disease. There are morphological differences in the 
liver between genders. Thus, hepatic damage may pro-
duce different consequences in men and women in ongo-
ing primitive diseases and during acquired conditions[2].
AUTOImmUNe lIveR DIseAses: 
pRImARy bIlIARy CIRRhOsIs, 
AUTOImmUNe hepATITIs AND pRImARy 
sCleROsINg ChOlANgITIs
Previous studies have examined gender differences in the 
immune system, and suggest that estrogen and androgen 
may modulate the immune system. Women have a sig-
nificantly higher number of  CD4+ T lymphocytes and a 
higher CD4+/CD8+ ratio than men[3].
Additionally, the secretion of  interferon-γ (IFN-γ) 
and interleukin (IL)-10 was enhanced after the addi-
tion of  estrogen in T-cell clones isolated from women[4]. 
Conversely, androgen inhibited, the secretions of  IFN-γ, 
IL-4, and IL-5 in murine T cells[5].
These findings suggest that gender differences could 
have a role in autoimmune diseases.
The best example demonstrating gender differences is 
PBC.
PBC is a chronic cholestatic liver disease character-
ized by immune-mediated inflammatory destruction of  
the small intrahepatic bile ducts, and fibrosis. PBC can 
progress to cirrhosis and subsequent liver failure[6-8]. PBC 
is a typical female disease that occurs from 40-60 years of  
age[9]. The incidence rates in women and men range from 
3:1 to 22:1, with an average incidence rate in women of  
10:1[10]. The age at PBC diagnosis was found to be older 
in men (62 years) than in women (51 years)[11].
Numerous hypotheses have been formulated to jus-
tify this sex imbalance. For example, the effects of  sex 
hormones in lymphocyte maturation/activation and the 
synthesis of  antibodies and cytokines have been sug-
gested as contributing factors. Additionally, the immune-
modulatory effects of  estrogens during reproductive life, 
fetal microchimerism, skewing of  the X-chromosome in-
activation pattern and defects in sex chromosomes have 
also been suggested as factors[12]. Several studies have 
identified an increased incidence of  X haploinsufficiency 
in female patients[13,14]. 
A study by Selmi et al[15] indicates that epigenetic 
factors, such as X chromosome inactivation, may also 
be involved in the development of  PBC, and variable 
concordance rates of  PBC have been identified between 
twins. A recent study by Lleo et al[16] demonstrated how 
Y chromosome loss is associated with PBC in male pa-
tients. These epigenetic changes may be ideal targets for 
new personalized treatments, as suggested by cancer data. 
However, no convincing evidence has yet supported any 
of  these hypotheses. Males are less likely to be symptom-
atic than females. Females experience pruritus as a single 
symptom more often than males. It has been suggested 
that female sex hormones may be linked with pruritus. 
In addition, female sex hormones may cause more ab-
dominal pain/discomfort and constitutional symptoms 
(malaise, anorexia, weight loss, fatigue). In contrast, males 
experience more jaundice, jaundice with pruritus, and up-
per gastrointestinal bleeding[17]. 
The rates of  severe daytime somnolence and depres-
sive symptoms were found to be similar in males and 
females; in contrast, autonomic symptoms were more 
profound in females[18,19].
Concomitant autoimmune diseases such as, Sicca 
Syndrome, Scleroderma and Raynaud’s phenomenon, 
were shown to be less prevalent in men. These findings 
suggest that females are more likely to suffer concomi-
tant autoimmune disease than males. The complications 
of  hepatocellular carcinoma (HCC) in patients with PBC 
were reported to be significantly greater in men than in 
women[20]. Biochemical levels of  alkaline phosphatase 
(ALP), alanine aminotransferase (ALT) and gamma-glu-
tamyl transpeptidase (gGT) were reported to be slightly 
higher in symptomatic males compared to asymptomatic 
males, but both were higher than in females[21]. The only 
histological difference identified were that symptomatic 
female patients had more piecemeal necrosis of  the liver 
and that symptomatic males had more stainable copper 
storage than asymptomatic males. Additionally, symp-
tomatic females were reported to have more pseudoxan-
thomatous transformation than asymptomatic females[17]. 
AIH is a liver disease characterized by progressive in-
flammatory destruction of  the parenchyma. AIH is as-
sociated with the presence of  circulating autoantibodies, 
hypergammaglobulinemia and interface hepatitis on liver 
biopsy. AIH typically responds to immunosuppressive 
therapy[22].
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The etiology of  AIH is unknown, though both ge-
netic and environmental factors are involved. It has been 
suggested that the major mechanism of  liver damage is 
the failure of  impaired regulatory T cells to control im-
mune reactions against liver host antigens.
The actual prevalence of  AIH is unknown. AIH is 
characterized by a strong female preponderance (the fe-
male/male ratio is 3.6/1)[23]. There are no sex or gender 
differences in age, form of  clinical onset, frequency of  
symptomatic concurrent autoimmune diseases, and hu-
man leukocyte antigen DR (HLA DR) status. Several 
studies have demonstrated that in men, there is a minor 
frequency of  normalization of  ALT stages after 6 mo 
of  corticosteroid treatment[24]. However, men with AIH 
appeared to have better long-term survival and outcome 
than women[25]. In females the severity of  AIH was 
found to be likely to decrease during the second trimester 
of  pregnancy, when estrogen was secreted at high levels 
and acute AIH exacerbation occurred occur after deliv-
ery[26]. High levels of  estrogen are associated with an anti 
inflammatory milieu[27]. Moreover females have a higher 
frequency of  concurrent immunological disorders such 
as Sicca Syndrome at presentation than males.
Al-Chalabi et al[25] discovered the extended haplotype 
HLA A1-B8-DR3 (associated with increased susceptibil-
ity to AIH) was more than twice as prevalent in male pa-
tients as in female patients with AIH.
Primary sclerosing cholangitis (PSC) is a chronic cho-
lestatic liver disease characterized by progressive inflam-
mation and fibrosis of  the intrahepatic andextrahepatic 
bile ducts. PSC leads to cholestasis, progressive hepatic 
fibrosis and eventually decompensated cirrhosis[28,29].
The incidence of  PSC is 1:100000 people. Previous 
studies have demonstrated that PSC is more prevalent in 
men than in women (M > F 7:3). In the United States, 
between 62% and 70% of  patients are male[30]. The 
pathogenesis of  PSC is unclear because it is a complex 
immune-mediated disease. The most accepted theory 
is that in genetically predisposed individuals, the envi-
ronmental exposure to infective agents or toxins causes 
persistent immunemediated damage to cholangiocytes 
and progressive destruction of  bile ducts, which leads to 
chronic cholestasis[31] (Table 1).
AlCOhOlIC lIveR DIseAse
Alcohol abuse and its various complications are still wide-
spread in the Western world and represent a frequent 
cause of  hepatic damage. The excessive consumption of  
alcohol may cause hepatic steatosis, alcoholic hepatitis 
and cirrhosis. Alcoholic cirrhosis causes approximately 
40% of  deaths due to cirrhosis. The severe forms (hepa-
titis, cirrhosis) are associated with ingestion of  160 g/die 
of  alcohol in 10-20 years. The incidence of  alcoholic liver 
disease increases proportionally with the consumption of  
alcohol. Several surveys have demonstrated that hepatic 
damage develops faster in women than in men. In cases 
of  heavy drinkers with a weekly consumption of  336-492 
g, the relative risk of  developing cirrhosis was equivalent 
to 7 in men and 17 in women. Furthermore, the relative 
risk of  developing alcoholic liver disease was 3.7 in men 
and 7.3 in women. The factors regulating in the differ-
ences in susceptibility to alcoholic toxicity include the 
following: age during alcohol consumption, the manner 
of  alcohol consumption (with or without meals) and the 
nutritional state of  the individual[32].
Women are more susceptible to damage by alcohol 
compared to men, which leads to more advanced liver 
disease after alcohol consumption. It has been dem-
onstrated that, under the same conditions and assum-
ing equal doses of  alcohol, women reach higher blood 
ethanol concentrations than men. Moreover, it has 
been shown that females have a major risk of  hepatitis 
progression toward cirrhosis after abstaining from alco-
hol[33,34]. The causes attributed to these gender differences 
include differences in corporal structures, different enzy-
matic activity and hormonal differences. 
The process of  metabolizing a substance before it 
enter the general circulation is called first-pass metabo-
lism. Various studies have demonstrated that an isoform 
of  gastric alcohol dehydrogenase (ADH) has a main role 
in alcohol metabolism. ADH activity is linked to the first 
passage of  alcoholic metabolism and affects the blood 
ethanol concentration. At the gastric level, this enzyme is 
expressed less in women than in men. Furthermore, in a 
female heavy drinker the activity of  gastric ADH is practi-
cally absent. Therefore in women a majority of  alcohol 
reaches the liver directly, which may worsen the hepatic 
damages. Moreover, this situation contributes to the gen-
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Table 1  Gender differences in primary biliary cirrhosis and 
autoimmune hepatitis
Primary biliary cirrhosis Autoimmune hepatitis
M/F ratio 1:10 M/F ratio 1:3.6
Age at diagnosis higher in M than 
in F (62 yr vs 51 yr)
Normalization of ALT levels after 6 
mo of corticosteroid treatment less 
frequent in M than in F
M less symptomatic than F: 
pruritus, abdominal pain/
discomfort and constitutional 
symptoms more common in F; 
jaundice and upper gastrointestinal 
bleeding more common in M
Better long-term survival and 
outcome in M than F
Concomitant autoimmune 
diseases more common in F (sicca 
syndrome, sclerodermia, raynaud 
phenomenon), whereas HCC 
complication are significantly 
greater in M
Decrease of severity during second 
trimester of pregnancy and possible 
onset of acute exacerbation after 
delivery
ALP, ALT and gGT higher in M 
than F
Haplotype HLA A1-B8-DR3 more 
prevalent in M than in F
Piecemealnecrosis and 
pseudoxanthomatous
Higher frequency of concurrent 
immunological
trasformation greater in 
symptomatic F
disorders at presentation in F than 
M
HCC: Hepatocellular carcinoma; ALP: Alkaline phosphatase; ALT: Ala-
nine aminotransferase; gGT: Gamma-glutamyl transpeptidase; HLA: Hu-
man leukocyte antigen; F: Female; M: Male.
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abdominal fat is not different between genders, but it is 
affected by dietary lipid consumption[43]. Abdominal fat 
tissue is a major source of  free fatty acids and cytokines 
for the liver, and fat favors the early development of  insu-
lin resistance, dyslipidemia, and high blood pressure. The 
more favorable fat distribution in women demonstrates 
why women need a higher degree of  adiposity to achieve 
the same metabolic disturbances as men[44]. Subcutaneous 
and visceral adipose tissue types are influenced by age and 
gender. Visceral adipose tissue accumulates more rapidly 
with age and weight gain in males and postmenopausal 
females than in younger females[45]. The difference in the 
prevalence of  MS between genders has been attributed 
to sex hormones. Many studies have shown that, in post-
menopausal women, the distribution of  their body fat 
changes toward visceral adiposity[46]. There are differing 
reports in the literature concerning the association between 
gender and NASH. In some studies, NAFLD was approxi-
mately 1.5 times more prevalent in females than in males 
whereas other studies did not find any differences, between 
genders[47,48]. Some studies have shown that female gender 
is a risk factor for NASH[49], but the current literature pres-
ents conflicting results[50,51]. A population, based study sug-
gested that endogenous estrogens have a protective role in 
NASH, which may explain why the prevalence of  NAFLD 
increases in women over 50 years of  age[52].
In conclusion, although the sex differences for fibro-
sis in patients with NAFLD are not identical, women 
tend develop more, severe fibrosis than men[53].
The possible roles of  estrogen in hepatic lipid metabo-
lism and fibrosis require further investigation (Table 3).
ChRONIC hepATITIs b
Protracted treatment with nucleoside/nucleotide analogs 
has allowed for an improvement in the natural history of  
patients with chronic hepatitis B virus (HBV) infection 
by reducing the incidence of  cirrhosis and the risk of  
complications[54].
Over the last 20 years, the epidemiology of  HBV in-
fection has radically changed in Italy. At the beginning of  
the 1980, the rate of  HBV surface antigen (HBsAg) car-
riers in the general population was 3.5%, with peaks of  
10% in Southern Italy. The current prevalence of  carriers 
is less than 1%, and a majority of  carriers are male. The 
rate of  chronic infection is higher in men due to various 
factors and is widely studied. However, it is unclear if  
men are exposed to more viruses, or if  men have a less 
effective immune response in eliminating. The major re-
der differences in blood concentration and contributes to 
unfavorable consequences of  alcohol use[35]. Another cause 
of  female vulnerability to the toxic effects of  alcohol is the 
reduced content of  corporal water compared to men[36].
The quantity of  absorbed alcohol in the gastro-intesti-
nal system that is not metabolized by first-pass metabolism 
enters the circulation. Hepatic ADH, in the liver is princi-
pally involved in alcohol metabolism. The amount of  alco-
hol distributed in water determines the blood alcohol con-
centration. A woman has proportionally more fat and less 
water than a man. Thus, when the ethanol is distributed 
in water, the distribution volume in women is less, and the 
blood alcohol concentration is higher[35,37] (Table 2).
NAFlD
NAFLD is the most common chronic liver disease in the 
Western world, affecting 30% of  the general adult popu-
lation[38].
NAFLD is an umbrella term for a group of  diseases 
defined by a hepatic fat infiltration in > 5% of  hepato-
cytes, in the absence of  excessive alcohol intake. Exces-
sive alcohol intake is defined as two standard drinks 
(20 g ethanol) daily for men and one standard drink (10 
g ethanol) daily for women. NAFLD encompasses a 
histological spectrum ranging from simple steatosis to 
non-alcoholic steatohepatitis (NASH). NASH is defined 
by steatosis, hepatocellular damage and lobular inflam-
mation[39] in individuals without significant alcohol con-
sumption and without viral, congenital and autoimmune 
liver disease markers.
There have been parallel increases in the prevalence 
rates of  obesity, metabolic syndrome (hyperglycemia, 
visceral obesity, hyperlipidemia and hypertension) and 
NASH. As a result, NASH is considered part of  meta-
bolic syndrome (MS)[40].
MS is a risk factor for cardiovascular disease, its high 
prevalence has substantially affected public health in 
recent years[41]. There are varied reports in the literature 
regarding the gender distribution of  MS. Several studies 
report a higher incidence of  MS in men than in women, 
but the reverse has been shown in other reports[42].
The prevalence of  MS increases with the general 
population age and is more likely in black and Hispanic fe-
male populations. The accumulation of  hepatic and intra-
Table 2  Gender differences in alcoholic liver disease
Alcoholic liver disease (hepatic steatosis, alcoholic hepatitis, cirrhosis)
Hepatic damage faster in F than M
RR to develop cirrhosis 7 in M and 17 in F
RR to develop alcoholic liver disease 3, 7 in M and 7, 3 in F
F more susceptible to damage by alcohol than M: higher haematic 
concentration of ethanol in F than M: major risk of hepatitis progression 
toward cirrohosis (even after an absentation from alcohol) in F than M
Differences in corporal structures (content of corporal water), different 
enzymatic activity (gastric ADH expression and activity), hormonal
ADH: Alcohol dehydrogenase; RR: Relative risk; F: Female; M: Male.
Table 3  Non alcoholic fatty liver disease and gender
NAFLD and gender
Prevalence of MS in men and postmenopausal women
Prevalence of visceral adiposity in men and postmenopausal woman
Possible link to MS, NAFLD and sex hormones
NAFLD: Non alcoholic fatty liver disease; MS: Metabolic syndrome.
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sponse in females is caused by the position of  genes that 
determine the response, and most genes are located on 
the X chromosome. This hypothesis is supported by the 
female prevalence of  two hepatic autoimmune diseases 
(PBC and AIH)[55].
HBV does not meaningfully influence fertility, and 
contracting an HBV infection during a pregnancy does 
not increase morbidity or maternal or fetal mortality[56]. 
Recent evidences demonstrated that the increased produc-
tion of  proinflammatory cytokines in chronic hepatitis B 
(CHB)[57,58] may participate in the development of  compli-
cations, such as gestational diabetes, pre-delivery hemor-
rhages and pre-term delivery[59]. Furthermore, in women 
with cirrhosis, there are higher frequencies of  gestational 
hypertension, detachment of  the placenta and peripartum 
hemorrhages compared with healthy controls[60].
A normal pregnancy with elevated levels of  cortico-
steroid hormones and estrogens cause increased HBV 
viremia[61] and indices of  cytolysis (ALT)[62]. Moreover, 
there have been reported cases of  peripartum hepatitis 
with hepatic decompensation[63].
The main cause of  fetal HBV transmission is delivery. 
The administration of  immunoglobulins and an anti-
HBV vaccine may prevent fetal infection in more than 
85% of  children born from HbsAg+ mothers[64].
Other minor causes of  fetal and maternal transmis-
sion are intrauterine transmission (HBV may reach the 
foetus through the placental barrier)[65] and transmission 
during breastfeeding through virus ingestion or by con-
tact with maternal cutaneous lesions[66].
There is currently no clear therapeutic way to prevent 
viral transmission. The pre-delivery administration of  
immunoglobulins has yelded discordant results[67,68]. The 
study by Beasley demonstrated that the administration of  
immunoglobulins and anti-HBV vaccine within 12 h of  
birth reduced the frequency of  HBV transmission from 
> 90% to 26%[69,70].
A 2012 Chinese study evaluated the safety of  lamivu-
dine treatment for CHB in early pregnancy. This study 
examined 92 chronic HBV-infected pregnant women who 
received Lamivudine treatment either before pregnancy 
or in early pregnancy. These women were not co-infected 
with hepatitis C virus (HCV), human immunodeficiency 
virus, cytomegalovirus, or other viruses. Adverse events 
were observed throughout the entire pregnancy and peri-
natal period. The effectiveness of  Lamivudine treatment 
for blocking mother-to-infant transmission of  HBV 
was evaluated. The data showed that treatment does not 
increase complications or adverse events for mothers 
during pregnancy or the perinatal period. Additionaly 
no effect on fertilization or embryonic development was 
found, and treatment did not increase the incidence of  
congenital abnormalities in infants. Furthermore, treat-
ment reduced the rate of  mother-to-infant transmis-
sion[71]. A case report described a treatment with triple 
therapy of  Lamivudine, IFN-beta and prednisolone for 
acute CHB exacerbation during pregnancy. The patient’s 
liver enzymes became elevated toward the end of  the first 
trimester. She was treated with Lamivudine, interferon-
beta and steroids early in the second trimester. After this 
treatment, aminotransferase levels rapidly normalized 
within 4 wk. Lamivudine was continued until delivery. 
Spontaneous delivery occurred at 37 wk of  gestation. 
There were not congenital anomalies, and fetal growth 
was found to be within normal reference ranges. This 
case report suggests that combination therapy with Lami-
vudine, IFN-beta and steroids may be safely used during 
the pregnancy to treat acute CHB exacerbations[72].
There are ongoing studies investigating the use of  an-
tiviral medicines in mothers with high HBV DNA levels. 
Currently the oral antivirals Telbivudine and Tenofovir are 
classified as “FDA pregnancy category B”, whereas the 
other antiviral drugs are classified as “FDA pregnancy cat-
egory C”. A recent meta-analysis has demonstrated that 
Telbivudine use in the final stage of  pregnancy is effective 
in preventing or reducing the perinatal transmission of  
HBV without meaningful or unfavorable effects[73].
Some data exist on tenofovir in HIV positive women 
but these data show increased congenital malformations, 
kidney damage and distorted bone metabolism after ex-
posure in utero[74] (Table 4).
ChRONIC hepATITIs C
HCV infection affects 130-170 million people worldwide, 
which is approximately 2%-3% of  the global population. 
HCV is transmitted by parenteral routes, such as contact 
with infected blood or contaminated materials and intra-
venous drugs injection with contaminated syringes. Al-
though less common, HCV can be transmitted by sexual 
contact with HCV-positive partners[75,76]. Several studies 
have demonstrated that women have less altered hepatic 
biochemical tests and lower rates of  fibrosis progres-
sion[77]. These findings are related to the protective ef-
fects of  estrogens, which possess anti-fibrotic properties. 
Estrogens have a role in blocking fibrogenesis in hepatic 
Table 4  Chronic hepatitis B during the pregnancy and in the 
foetus
HBV and pregnancy HBV and foetus
Not increases in maternal morbidity 
and mortality
Maternal transmission: during 
delivery, intrauterine transmission 
and during breast feeding
Increases HBV viremia levels and 
indices of cytolysis
Discordant results from pre-
delivery administration of Ig and 
anti-HBV vaccine
Development of complications 
(gestational diabetes, pre-delivery 
hemorrhages and pre-term delivery)
Administration of Ig and anti-HBV 
vaccine during delivery to prevent 
infection
Higher frequency of gestational 
hypertension, detachment 
of placenta and peripartum 
hemorrhages in F with cirrhosis 
Cases of peripartum hepatitis with 
hepatic decompensation
Ongoing studies about the use 
of antiviral medicines in F with 
high HBV DNA levels to prevent 
perinataltransmission (telbivudine 
and tenofovir in FDA pregnancy 
category B)
HBV: Hepatitis B virus; F: Female; FDA: Food and drug administration.
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stellate cells. The notion that estrogen has a protective 
role was also suggested by evidence that menopause is 
associated with an accelerated rate of  fibrotic progres-
sion and that hormone replacement therapy may mini-
mize this effect[78]. The prevalence of  HCV infection in 
pregnancy is 1%-2% in the United States and Europe. 
However, the rate of  HCV, may reach up to 8% in some 
developing countries[79].
The documented mother-to-child transmission 
(MTCT) frequency of  HCV is approximately 5%-10%[80]. 
The pathogenesis of  HCV infection during pregnancy 
and the neonatal period is unclear. During pregnancy, 
the maternal immune system has to develop tolerance to 
paternal antigenes to avoid any maternal immune assault 
towards the fetus. Simultaneously, the maternal immune 
system most maintain active immunity against HCV to 
protect both the mother and fetus from infection. This 
modulation of  immune responses is different during each 
stage of  pregnancy[81]. In developed countries, vertical 
transmission is the main cause of  pediatric-HCV infec-
tion. The factors demonstrated to increase the risk of  
maternal-fetal transmission include amniocentesis, the 
extended breaking of  the membranes and an elevated 
viral load in the mother. Perinatal HCV transmission is 
confined to women with HCV RNA present in their pe-
ripheral blood; it occurs rarely if  the maternal viral load 
less than 1 × 105 HCV RNA copies/mL of  plasma[82].
Two previous studies demonstrated that high levels 
of  ALT in the year before pregnancy are linked with a 
higher maternal-fetal transmission rate. These results sug-
gest that the development of  liver damage in the mother 
is a potential risk factor for HCV transmission[83]. Fur-
thermore, HCV infection and signs of  viral replications 
in maternal peripheral blood mononuclear cells enhances 
the rate of  transmission[84]. Conversely, breastfeeding and 
genotype do not appear to be linked to MTCT. A co-
infection with HIV virus increases the likelihood of  ver-
tical HCV transmission by 90%[85]. 
The standard treatment for chronic HCV infection 
is PEG-IFNα and ribavirin. Recently, the new antiviral 
medicines, telaprevir and boceprevir were introduced[86].
Little is known about the real impact of  gender on 
the characteristics that influence the efficacy and safety 
of  chronic hepatitis C treatment. Several studies have 
demonstrated that the sustained virological response 
(SVR) rate is significantly higher in women than in men, 
and fertile women with normal genotypes have a 100% 
chance of  obtaining a SVR. Therefore the administration 
of  combined therapy is not recommended during preg-
nancy (Pregnancy FDA Category X)[87] (Table 5).
geNeTIC hemOChROmATOsIs
Iron is essential for many biological processes. The liver 
stores for iron and plays a central role in the regulation of  
iron metabolism. The liver synthesizes hepcidin, which is 
the most important iron regulatory hormone.
Genetic hemochromatosis (GH) is a prevalent iron 
overload disorder in the Caucasian population. Patients 
absorb more than the normal amount of  iron through 
the intestine. Hepcidin is suggested to play a role in GH.
GH is not a gender-specific disease, but more males 
than females present symptoms and signs of  hemochro-
matosis. Men accumulate more iron and have a higher 
incidence of  liver injury[88].
The clinical symptoms of  GH usually begin later in 
women than in men, likely due to the physiological loss 
of  blood in women of  childbearing age. The gender-
specific regulation of  hepcidin synthesis in the liver may 
play a role in this process[89].
The prevalence of  the disease in men may also be 
explained by the greater extrahepatic deposition of  iron 
in males than in females. In addition, serum ferritin lev-
els are higher in men, which suggests that men have in-
creased extrahepatic iron stores[90].
In conclusion, the clinical presentation of  GH is dif-
ferent between women and men. Both liver disease and 
diabetes are more common in men, whereas fatigue and 
pigmentation are more common in women[91].
CONClUsION
Gender medicine focuses the scientific community on 
understanding and analyzing clinical, patho-physiological, 
prevention and treatment differences in diseases that are 
equally represented in men and women[1].
Current medicine offers better care through the study 
of  disease mechanisms based on gender differences by 
focusing on the incidence and etiology of  pathologies, 
clinical objectives and the response to therapies[33]. The 
purpose of  this fields is to provide the best treatment 
possible to each individual man and woman based on sci-
entific evidences.
This review emphasized the importance of  appropri-
ate management of  viral chronic hepatitis during preg-
nancy and summarized the strategies to prevent mother-
to-child transmission. The review focused on maternal 
and perinatal outcomes, disease progression and its 
impact on pregnancy, and the new effective drugs used to 
Table 5  Chronic hepatitis C during the pregnancy
Chronic hepatis C and pregnancy
Frequency of HCV MTCT is 5%-10%
Vertical transmission is the main cause of pediatric HCV infection
Factors increasing the risk of MTCT: amniocentesis, extended breaking 
of the membranes and elevated viral load in the mother
High levels of ALT in the previous year of pregnancy are linked with a 
higher MTCT rate
Signs of viral replications is maternal peripheral blood mononuclear 
cells enhance vertical transmission
Breastfeeding and genotype are not linked to MTCT
Presence of HCV-HIV coinfection increases MTCT by 90%
The administration of combined therapy is not recommended during 
pregnancy
HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; MTCT: 
Mother-to-child transmission; ALT: Alanine aminotransferase.
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prevent maternal infection transmission without signifi-
cant adverse effects or complications. In summary, based 
on the current literature, we recommend close maternal-
fetal monitoring during pregnancy and suggest that all 
available treatment options be considered in the future.
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